BioAge Labs BIOA 深 沪
已收盘 10-02 16:00:00 美东时间
6.61
-0.200
-2.94%
华盛通- 最 高6.92
- 今 开6.92
- 成交量 87.00万股
- 最 低 6.47
- 昨 收 6.81
- 总市值 3.03亿
- 52周最高 25.955
- 市盈率 静 --
- 换手率 1.90%
- 52周最低 5.04
- 委 比 13.15%
- 总股本 4589.69万
- 历史最高 26.62
- 量 比 1.36
- 振 幅 6.61%
- 历史最低 0.156
- 每 手 1
- 风险率 5.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioAge Labs initiates Phase 2 trial for BGE-102
BioAge Labs, Inc. ( ($BIOA) ) just unveiled an update. BioAge Labs announced th...
10-03 04:54
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs, Inc. announced its participation in two upcoming investor conferences: the ROTH Healthcare Opportunities Conference in New York on September 29, 2026, and the Stifel Virtual Cardiometabolic Forum on September 30, 2026. Key executives, including BJ Sullivan, Dov Goldstein, MD, and Alexis Jakubowski, will engage in one-on-one meetings and a fireside chat. BioAge, a clinical-stage biopharmaceutical company, is developing therapeutic can...
09-25 20:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
09-08 23:25
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomize...
09-08 20:06
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
BioAge Labs has initiated a Phase 2 trial (QUELL-DME) evaluating BGE-102, an oral NLRP3 inhibitor, for treating diabetic macular edema (DME). The randomized, controlled study involving ~180 participants will assess BGE-102 as monotherapy and in combination with anti-VEGF therapy, with the primary endpoint being change in best-corrected visual acuity at week 12. Topline results are expected in H2 2027. BGE-102's potential benefits extend to other ...
09-08 12:00
Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $2.451 million which...
08-06 05:19
美股牛股 | Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股
Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股；AAOI升逾16%，英伟达官宣CPO步入量产提振板块>>
08-04 19:06
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
